Iron and Alzheimer's Disease: The Role of Amyloid-β and Iron Chelators
Author Information
Author(s): Avramovich-Tirosh Yael, Amit Tamar, Bar-Am Orit, Weinreb Orly, Youdim Moussa BH
Primary Institution: Technion-Faculty of Medicine
Hypothesis
The study hypothesizes that oxidative stress-induced intracellular iron may stimulate APP holo-protein translation and subsequently the generation of its cleavage product, Aβ, as a compensatory response that reduces oxidative stress.
Conclusion
The study concludes that Aβ production may serve as a neuroprotective response to reduce oxidative stress damage, and that iron chelators targeting the APP 5'UTR may be promising therapeutic agents for Alzheimer's disease.
Supporting Evidence
- Aβ has iron chelation sites and may reduce iron-induced neurotoxicity.
- Iron chelators can target the APP 5'UTR and reduce APP translation and Aβ levels.
- Oxidative stress promotes Aβ generation as a protective response.
- High levels of iron are found in the brains of Alzheimer's disease patients.
- Intramuscular administration of DFO slowed clinical progression of Alzheimer's dementia.
Takeaway
This study suggests that a protein called Aβ can help protect brain cells from damage caused by iron, and that drugs that remove iron might help treat Alzheimer's disease.
Methodology
The study reviews existing literature and discusses the physiological and pathological roles of iron in Alzheimer's disease, focusing on the APP mRNA 5'UTR and the effects of iron chelators.
Limitations
The study primarily reviews existing literature and may not include original experimental data.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website